ライフサイエンスコーパス: histocompatibility

1 ein TS1 CD4 cells specific for a model minor histocompatibility Ag (miHA) induce GVHD in miHA-positiv

2 ally processed, ubiquitously expressed minor histocompatibility Ag (miHAg) with a proven role in GVHD

3 oth MHC-mismatched and MHC-matched but minor histocompatibility Ag-mismatched models driven by CD4 T

4 from personnel in 16 transplant centers, 19 histocompatibility and immunogenetics laboratories, tran

5 ed down for non-"quality" reasons, primarily histocompatibility and size.

6 compatibility complex-matched multiple minor histocompatibility antigen-mismatched alloHCT using bone

7 In both a minor histocompatibility antigen-mismatched as well as a MHC-h

8 tly suppressed the clonal expansion of minor histocompatibility antigen-specific CD8 T cells during t

9 itude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with sel

10 Expression of major histocompatibility antigens class-2 (MHC-II) under non-i

11 Allogeneic antibodies against minor histocompatibility antigens encoded on the Y chromosome

12 by increased recipient mismatching for major histocompatibility antigens or minor histocompatibility

13 ncluding recognition of sex-determined minor histocompatibility antigens, influence of sex hormones o

14 r major histocompatibility antigens or minor histocompatibility antigens.

15 eptance of cardiac allografts across a major histocompatibility barrier.

16 anufacturing and enable cell transfer across histocompatibility barriers.

17 bulin (beta2m), a key component of the major histocompatibility class I complex, can aggregate into f

18 The major histocompatibility class I-like antigen-presenting molec

19 CNS injury can occur independently of major histocompatibility class II (MHCII) signaling to T cell

20 ffinity of CD4 for its ligand, peptide-major histocompatibility class II (pMHC II) on antigen-present

21 nd BRAFV600E, causes expression of the major histocompatibility class II antigen presentation apparat

22 ession of CIITA, a master regulator of major histocompatibility class II gene transcription.

23 In patients, expression of major histocompatibility class II in melanoma is linked to fav

24 Ags), which engage lateral surfaces of major histocompatibility class II molecules and T-cell recepto

25 Whereas major histocompatibility class-1 (MH1) proteins present peptid

26 (P < 2.5e-05) vGWAS signals within the major histocompatibility complex (MHC) across all three study

27 primary Sjogren's syndrome (pSS) with Major Histocompatibility Complex (MHC) alleles is quintessenti

28 hood of neoantigen presentation by the major histocompatibility complex (MHC) and subsequent recognit

29 in constructs were transplanted across major histocompatibility complex (MHC) barriers in a porcine a

30 F3 downregulates expression of surface major histocompatibility complex (MHC) class I and class II mo

31 s tumour antigen peptides presented by major histocompatibility complex (MHC) class I and class II mo

32 ) maturation, as well as inhibition of major histocompatibility complex (MHC) class I and class II.

33 The direct major histocompatibility complex (MHC) class I antigen present

34 Here we found a central role for major histocompatibility complex (MHC) class I in controlling

35 obulin-like receptors (KIRs) and their major histocompatibility complex (MHC) class I ligands.

36 Individuals expressing the major histocompatibility complex (MHC) class I molecule HLA-A2

37 Major histocompatibility complex (MHC) class I molecules deter

38 ion of peptides that were presented on major histocompatibility complex (MHC) class I molecules in an

39 receptors, many of which interact with major histocompatibility complex (MHC) class I molecules.

40 , are presented at the cell surface by major histocompatibility complex (MHC) class I molecules.

41 exogenous antigens to T cells via both major histocompatibility complex (MHC) class I pathways and MH

42 Peptide antigen presentation by major histocompatibility complex (MHC) class I proteins initia

43 cells also had decreased expression of major histocompatibility complex (MHC) class I proteins, a hal

44 otein signaling, and downregulation of major histocompatibility complex (MHC) class I surface express

45 ls is characteristically restricted by major histocompatibility complex (MHC) class I, although rare

46 ognize lipid antigens presented by the major histocompatibility complex (MHC) class I-like molecule,

47 Innate variant TFH cells required major histocompatibility complex (MHC) class I-like signaling

48 type of proteasome destined to improve major histocompatibility complex (MHC) class I-mediated antige

49 This study investigated the role of major histocompatibility complex (MHC) class I-related chain A

50 bacterial riboflavin presented by the major histocompatibility complex (MHC) class I-related molecul

51 rrent strategies use genes that encode major histocompatibility complex (MHC) class I-restricted T-ce

52 model, we found that the expression of major histocompatibility complex (MHC) class II and CD74 in B

53 Suppression of major histocompatibility complex (MHC) class II antigen presen

54 ools of dengue virus-derived predicted major histocompatibility complex (MHC) class II binding peptid

55 guished CD4(+) T cells selected by the major histocompatibility complex (MHC) class II molecule I-A(g

56 es antigenic peptides for loading onto major histocompatibility complex (MHC) class II molecules.

57 show that antigen presentation within major histocompatibility complex (MHC) class II of donor dendr

58 Recently, major histocompatibility complex (MHC) class II tetramers have

59 ation, including the gene encoding the major histocompatibility complex (MHC) class II transactivator

60 Because major histocompatibility complex (MHC) class II(+) cells are m

61 mphocytes to be targeted by a panel of major histocompatibility complex (MHC) class II-matched CD4(+)

62 s, CD11b(+) myeloid-derived cells, and major histocompatibility complex (MHC) class II-positive antig

63 renal infiltration with ED1 (CD68) or major histocompatibility complex (MHC) class II-positive cells

64 a complementary approach, we generated major histocompatibility complex (MHC) class II-restricted T c

65 Also, individuals with locally rare major histocompatibility complex (MHC) class IIb genotypes wer

66 The major histocompatibility complex (MHC) contains the most polym

67 ne marrow transplantation (BMT) across major histocompatibility complex (MHC) disparities and may be

68 Genes of the major histocompatibility complex (MHC) encode receptor molecul

69 evious studies have indicated that the major histocompatibility complex (MHC) genes play the most pro

70 que group of animals that have limited major histocompatibility complex (MHC) genetic diversity, such

71 in immunogenicity depends on both host major histocompatibility complex (MHC) genetics and the likeli

72 association with AD risk occurred with major histocompatibility complex (MHC) haplotype A*03:01 B*07:

73 crossreactivity toward multiple other major histocompatibility complex (MHC) haplotypes.

74 The chicken major histocompatibility complex (MHC) has strong genetic asso

75 Disruption of the non-classical Major Histocompatibility Complex (MHC) Ib molecule Qa-1 impair

76 perate simultaneously by analysing the major histocompatibility complex (MHC) in guppies (Poecilia re

77 T cell antigen receptor (TCR)-peptide-major histocompatibility complex (MHC) interface is composed o

78 The Major Histocompatibility Complex (MHC) is a key component of t

79 The binding between a peptide and a major histocompatibility complex (MHC) is one of the most impo

80 Continuous contact with self-major histocompatibility complex (MHC) ligands is essential fo

81 icrosatellite, structural variant, and major histocompatibility complex (MHC) loci, confirming that i

82 lation level involves variation in the major histocompatibility complex (MHC) locus, but the genes an

83 its feasibility in a clinical setting.Major histocompatibility complex (MHC) matching improves graft

84 rates cGVHD in multiple models: a full major histocompatibility complex (MHC) mismatch model of multi

85 Evidence is mounting that the major histocompatibility complex (MHC) molecule HLA-F (human l

86 otype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule.

87 gen when presented in the context of a major histocompatibility complex (MHC) molecule.

88 tor (TCR) and peptide presented by the major histocompatibility complex (MHC) molecule.

89 and antigenic peptide in complex with major histocompatibility complex (MHC) molecules is a crucial

90 eta T cell receptor (TCR) with peptide-major histocompatibility complex (MHC) molecules on antigen-pr

91 nd was largely restricted by classical major histocompatibility complex (MHC) molecules.

92 spond to peptide epitopes presented by major histocompatibility complex (MHC) molecules.

93 e interacts with peptides presented by major histocompatibility complex (MHC) molecules.

94 Here we use peptide-major histocompatibility complex (MHC) multimers labeled with

95 Major Histocompatibility Complex (MHC) or Human Leukocyte Anti

96 table to either a TCR focus on exposed major histocompatibility complex (MHC) polymorphisms or the de

97 that was dependent on the nonclassical major histocompatibility complex (MHC) protein CD1d, which pre

98 e response process is regulated by the major histocompatibility complex (MHC) protein which is encode

99 th which complexes of self peptide and major histocompatibility complex (MHC) proteins are recognized

100 s reactive to complexes of peptide and major histocompatibility complex (MHC) proteins, many other ty

101 ants expanding throughout the extended major histocompatibility complex (MHC) region and 68 non-LS-as

102 The mammalian Major Histocompatibility Complex (MHC) region contains several

103 Multiple single variants within the major histocompatibility complex (MHC) region were observed to

104 ith the strongest association from the major histocompatibility complex (MHC) region.

105 influenced by genetic variation in the major histocompatibility complex (MHC) region.

106 88) for HPV8 seropositivity within the major histocompatibility complex (MHC) region.

107 sociations, in the IL28B/IFNL4 and the major histocompatibility complex (MHC) regions, with spontaneo

108 Major histocompatibility complex (MHC) restriction is a fundam

109 Major histocompatibility complex (MHC) restriction is a unique

110 t mapping, independent localization of major histocompatibility complex (MHC) risk from classical HLA

111 ere up to 94.4% pure, as determined by major histocompatibility complex (MHC) tetramer analysis.

112 uding the tumor necrosis factor (TNF), major histocompatibility complex (MHC), interleukin 23 recepto

113 ve been implicated in vertebrates: the major histocompatibility complex (MHC), which could be vertebr

114 ecipients, most prominently within the major histocompatibility complex (MHC), which encodes human le

115 Here we identified 107 major histocompatibility complex (MHC)-bound HIV peptides dire

116 tributed to an absence of cell surface major histocompatibility complex (MHC)-I molecule expression.

117 We now show that major histocompatibility complex (MHC)-II and its master regul

118 Here we show the efficacy of major histocompatibility complex (MHC)-matched allogeneic neur

119 In a full major histocompatibility complex (MHC)-mismatched, multiorgan

120 rate diverse T cell subsets, including major histocompatibility complex (MHC)-restricted alphabeta T

121 strong evidence of association to the major histocompatibility complex (MHC).

122 One interesting example is the chicken major histocompatibility complex (MHC).

123 from interactions between the TCR and major histocompatibility complex (MHC).

124 odels, have become synonymous with the major histocompatibility complex (MHC).

125 ll selection by sensing the density of major histocompatibility complex (MHC):peptide antigen complex

126 n of IL-12, and inhibition of class II major histocompatibility complex (MHC-II) molecules in infecte

127 l receptor (TCR) with a peptide-loaded major histocompatibility complex (p/MHC) leads to T-cell activ

128 ed progressively with lowering peptide major histocompatibility complex (pMHC) affinity.

129 hich T cell receptor (TCR) and peptide major histocompatibility complex (pMHC) interact.

130 is interaction of pre-TCR with peptide-major histocompatibility complex (pMHC) molecules has recently

131 ters its antigenic ligand, the peptide-major histocompatibility complex (pMHC), on the surface of ant

132 sequences using a panel of peptide and major histocompatibility complex (pMHC)-tetramer-sorted cells

133 ctors aside from intrinsic TCR-peptide-major histocompatibility complex (TCR-peptide-MHC) reactivity

134 n of Parkinson's disease with specific major histocompatibility complex alleles.

135 responses upon antigen presentation by major histocompatibility complex and cognate alphabeta T cell

136 Polymorphisms related to the major histocompatibility complex and interferon (IFN)-gamma ge

137 he transmembrane complexes between the major histocompatibility complex and the T cell receptor (Sign

138 iable nature of this protein, a common major histocompatibility complex class (MHC-II) epitope was id

139 ypes for their ability to downregulate major histocompatibility complex class A (MHC-A) and MHC-B fro

140 markedly more effective at suppressing major histocompatibility complex class I (MHC I) display on th

141 lls depends on antigen presentation by major histocompatibility complex class I (MHC I) molecules.

142 Major histocompatibility complex class I (MHC I) positive sele

143 Certain major histocompatibility complex class I (MHC-I) alleles (e.g.

144 expectedly and uniquely degraded Nef's major histocompatibility complex class I (MHC-I) downregulator

145 35A) bearing a mutation in the cognate major histocompatibility complex class I (MHC-I) epitope that

146 The NLR family member NLRC5 regulates major histocompatibility complex class I (MHC-I) expression du

147 ow cytometry analyses showed decreased major histocompatibility complex class I (MHC-I) expression in

148 Peptide loading of major histocompatibility complex class I (MHC-I) molecules is

149 S5 were also elicited, as evidenced by major histocompatibility complex class I (MHC-I) tetramer stai

150 ects with ALS reduce the expression of major histocompatibility complex class I (MHCI) molecules on M

151 Major histocompatibility complex class I (MHCI) proteins have

152 immunity is the recognition of peptide-major histocompatibility complex class I (p-MHC I) proteins di

153 eraction affinity with cognate peptide-major histocompatibility complex class I (pMHCI).

154 mononuclear cell DEGs associated with major histocompatibility complex class I and natural killer ce

155 l immunoglobulin-like receptors (KIR), major histocompatibility complex class I chain-related genes (

156 e, the identification of antigens with major histocompatibility complex class I epitopes is a crucial

157 es of perifascicular fiber atrophy and major histocompatibility complex class I expression.

158 ceptor (iKIR) for which the respective major histocompatibility complex class I ligand is absent on l

159 enerating peptides that could serve as major histocompatibility complex class I ligands, marking cell

160 Major histocompatibility complex class I molecules (MHC I) hel

161 the interaction of Ly49 receptors with major histocompatibility complex class I molecules (MHC-I).

162 owth of melanoma cell lines expressing major histocompatibility complex class I molecules at high lev

163 tudy, we evaluated the contribution of major histocompatibility complex class I molecules to brain at

164 reticulum and subsequent loading onto major histocompatibility complex class I molecules to trigger

165 Major histocompatibility complex class I polypeptide-related s

166 bacterial metabolites presented by the major histocompatibility complex class I-related molecule MR1.

167 n led to loss of surface expression of major histocompatibility complex class I.

168 with peptides bound to the polymorphic major histocompatibility complex class Ia (MHC-Ia) and class I

169 aracterized by increased expression of major histocompatibility complex class II (approximately 2.0-f

170 loped a mouse strain that lacks murine major histocompatibility complex class II (MHC II) and instead

171 oculation with M. canis also decreased major histocompatibility complex class II (MHC-II) antigen exp

172 Mtb has been reported to block major histocompatibility complex class II (MHC-II) antigen pre

173 TA) is essential for the expression of major histocompatibility complex class II (MHC-II) genes; howe

174 Major histocompatibility complex class II (MHC-II) molecules a

175 Major histocompatibility complex class II (MHC-II) molecules p

176 sentation in addition to the classical major histocompatibility complex class II (MHC-II) peptide pre

177 or mouse CMV (MCMV) epitopes and use a major histocompatibility complex class II (MHC-II) tetramer to

178 the beta subunit of the non-classical major histocompatibility complex class II (MHC-II)-like molecu

179 s antigen-specific CD4(+) T cells in a major histocompatibility complex class II (MHC-II; HLA-DR)-dep

180 A polymorphism at beta57 in some major histocompatibility complex class II (MHCII) alleles of r

181 alpha-syn fibrils, with attenuation of major histocompatibility complex class II (MHCII) and proinfla

182 id cell (ILC3)-intrinsic expression of major histocompatibility complex class II (MHCII) is regulated

183 The major histocompatibility complex class II (MHCII) is ubiquitin

184 DC-to-MC molecule transfers including major histocompatibility complex class II (MHCII) proteins ena

185 une-disease-relevant peptides bound to major histocompatibility complex class II (pMHCII) molecules t

186 en naive CD4(+) T cells engage peptide+major histocompatibility complex class II and co-stimulatory m

187 th AZD1480 inhibited alpha-SYN-induced major histocompatibility complex Class II and inflammatory gen

188 is a superantigen that cross-links the major histocompatibility complex class II and specific V-beta

189 x) to induce infertility in mice whose major histocompatibility complex class II antigen was replaced

190 epitopes that are predicted to be good major histocompatibility complex class II binders and at the s

191 Major histocompatibility complex class II binding and T-cell r

192 ing class II transactivator attenuates major histocompatibility complex class II expression on endoth

193 two transcription factors dedicated to major histocompatibility complex class II expression, suggesti

194 antigen processing rather than peptide-major histocompatibility complex class II loading.

195 We used major histocompatibility complex class II mismatched C57BL/6N

196 had stronger myocardial expression of major histocompatibility complex class II molecule and enhance

197 ng a high density of peptides bound to major histocompatibility complex class II molecules (pMHC) are

198 d the presentation of self antigens by major histocompatibility complex class II molecules in an infl

199 Wild-type LCs upregulated major histocompatibility complex class II molecules, migrated

200 ernalized antigens in combination with major histocompatibility complex class II molecules.

201 ely 30-50%) in expression of CD11b and major histocompatibility complex class II on both monocytes an

202 Furthermore, silencing of major histocompatibility complex class II reduces allogeneic T

203 of VZV-specific CD4(+) T cells with an major histocompatibility complex class II tetramer (epitope of

204 Direct ex vivo staining with peptide-major histocompatibility complex class II tetramers enabled co

205 Moreover, the number of mast cells, major histocompatibility complex class II+, or CD11b+ immunocy

206 Major histocompatibility complex class II, a marker of microgl

207 factor, and intragraft transcripts for major histocompatibility complex class II, Toll-like receptors

208 oss-link the T cell receptor (TCR) and major histocompatibility complex class II, triggering a massiv

209 restoration of mature macrophages and major histocompatibility complex class II-expressing dendritic

210 MO2, CD58, and stromal-1-signature and major histocompatibility complex class II-signature genes, whi

211 Major histocompatibility complex E (MHC-E) is a highly conserv

212 e-mapping of challenging regions, e.g. major histocompatibility complex for schizophrenia.

213 and expertly curates sequences of the major histocompatibility complex from non-human species and pr

214 d highly (Balb/c in C57BL/6) stringent major histocompatibility complex fully mismatched mouse models

215 non-human leukocyte antigen genes of 3 major histocompatibility complex gene classes but not at allel

216 ry receptor, ATP-binding cassette, and major histocompatibility complex genes.

217 ies to provide 100 completely resolved major histocompatibility complex haplotypes and to resolve maj

218 Those results revealed two major histocompatibility complex haplotypes associated with sy

219 al localization of DCs specialized for major histocompatibility complex I (MHC I) and MHC II presenta

220 he peptides that bind to non-classical major histocompatibility complex Ib Qa-1 molecules and are rec

221 tumour neo-antigens in the context of major histocompatibility complex II (MHCII) are highly desirab

222 lonal stimulation, and displayed lower major histocompatibility complex II expression by antigen-pres

223 d lysosome tubulation and secretion of major histocompatibility complex II in macrophages and dendrit

224 Major histocompatibility complex II tetramers corresponding to

225 creased number of microglia expressing major histocompatibility complex II.

226 ts, resident cardiac MHCII(LO)CCR2(-) (major histocompatibility complex II/C-C motif chemokine recept

227 ctly or related to the function of the Major Histocompatibility Complex in a number of different spec

228 vestigate the plasticity of a class II major histocompatibility complex in the absence of a bound pep

229 Continuous contact with self-major histocompatibility complex ligands is essential for the

230 rmed in mice across varying degrees of major histocompatibility complex mismatch combinations.

231 himerism model receiving BCNU across a major histocompatibility complex mismatch.

232 in exhibited >100-day survival of full major histocompatibility complex mismatched allografts, wherea

233 We performed major histocompatibility complex mismatched aorta to carotid a

234 went nonmyeloablative conditioning and major histocompatibility complex mismatched BMT with or withou

235 ges a peptide bound to the restricting major histocompatibility complex molecule (pMHC), it transmits

236 foreign peptide antigens presented in major histocompatibility complex molecules (pMHC) is essential

237 ic peptides within class I or class II major histocompatibility complex molecules (pMHCI or pMHCII, r

238 ts to ablate EC expression of class II major histocompatibility complex molecules and with it, the ca

239 Ablation of endothelial cell class II major histocompatibility complex molecules by small interferin

240 gnize peptide antigens associated with major histocompatibility complex molecules expressed on the su

241 s) recognize agonist peptides bound to major histocompatibility complex molecules on antigen-presenti

242 cell responses is complex and involves major histocompatibility complex molecules on transplanted org

243 cessors of antigen for presentation by major histocompatibility complex molecules, recent findings po

244 interleukin-21 and enriched by peptide-major histocompatibility complex multimer-guided cell sorting.

245 ic CD8 T cells were tracked down using major histocompatibility complex multimers against the immunod

246 Of the 110 non-major histocompatibility complex multiple sclerosis-associated

247 n antibody specific for human class II major histocompatibility complex products and used it to nonin

248 th the extremely polymorphic nature of major histocompatibility complex products within the species.

249 -DQ2.5 (DQA1*05/DQB1*02) is a class-II major histocompatibility complex protein associated with both

250 h foreign antigens bound to alleles of major histocompatibility complex proteins (MHC) that they were

251 HLA-A is a class I major histocompatibility complex receptor that presents peptid

252 als for oligoclonal band status in the major histocompatibility complex region for the rs9271640*A-rs

253 Association within the major histocompatibility complex region was also observed in e

254 ing antigen recognition independent of major histocompatibility complex restriction, while retaining

255 "A-into-O" transplantation (major histocompatibility complex syngeneic) was modeled by tra

256 amental difference between the CD1 and major histocompatibility complex systems is that all humans ex

257 single nucleotide polymorphisms of the major histocompatibility complex to precisely identify risk lo

258 to infiltration of activated class II major histocompatibility complex(+) T cells.

259 ignals of selection at lactase and the major histocompatibility complex, and in favor of blond hair a

260 numerous sites, often on incompatible major histocompatibility complex, and occurs in the context of

261 cated on 6p22.1, and covering lncRNAs (major histocompatibility complex, class I, A (HLA-A) and HLA c

262 classically used exosome markers, like major histocompatibility complex, flotillin, and heat-shock 70

263 Ever since the discovery of the major histocompatibility complex, scientific and clinical unde

264 ibility complex-1 tail, and subsequent major histocompatibility complex-1 downregulation and immune e

265 1 subunit of adaptor protein 1 and the major histocompatibility complex-1 tail, and subsequent major

266 s genetics, we performed genotyping of major histocompatibility complex-borne microsatellites and HLA

267 ion expression of inflammatory markers major histocompatibility complex-class II and IL6, lesion matr

268 High target peptide-major histocompatibility complex-I (pMHC) affinity and T cell

269 sented by the evolutionarily conserved major histocompatibility complex-like molecule MR1.

270 To elucidate major histocompatibility complex-linked systemic sclerosis gen

271 ormative clinically relevant RIC mouse major histocompatibility complex-matched alloHCT model by a pr

272 We investigated a murine model of major histocompatibility complex-matched multiple minor histoc

273 transplants were performed using minor major histocompatibility complex-mismatched B6.C-H2 donor hear

274 Using the major histocompatibility complex-mismatched mouse orthotopic l

275 hyma and the passenger leukocytes were major histocompatibility complex-mismatched to the recipients

276 uti rat and Balb mouse donors to fully major histocompatibility complex-mismatched Wistar Furth rat o

277 dney allograft rejection using a fully major histocompatibility complex-mismatched, life-sustaining,

278 nel support vector machines to predict major histocompatibility complex-peptide binding.

279 MAIT cells, surface expression of the major histocompatibility complex-related protein 1 (MR1), and

280 to confirm DSAs' specificity for allo-major histocompatibility complex.

281 arkinson's disease with alleles of the major histocompatibility complex.

282 The major-histocompatibility-complex-(MHC)-class-I-related molecul

283 o functionally engage multiple peptide-major histocompatibility complexes (pMHC) are unclear.

284 th autoimmune disease-relevant peptide-major histocompatibility complexes (pMHC) blunted autoimmune r

285 In searching for peptide-loaded major histocompatibility complexes (pMHCs), they must solve a

286 ctionally engage with multiple peptide-major histocompatibility complexes (pMHCs), we examined the IL

287 through interactions with peptide and major histocompatibility complexes (pMHCs).

288 ate chimerism and achieve tolerance in major histocompatibility disparate recipients have been develo

289 contributed to an advanced understanding of histocompatibility, graft-versus-host disease (GVHD), GV

290 donor T cells specific for particular minor histocompatibility (H) antigens.

291 of tumor-specific and host-restricted minor histocompatibility (H) antigens.

292 ns in genes that produce male-specific minor histocompatibility (H-Y) antigens.

293 peptide repertoire for presentation by major histocompatibility (MHC) class I molecules (pMHCs I) on

294 antation by transplanting MHC-matched, minor histocompatibility-mismatched grafts composed of purifie

295 rough recognition of peptides bound to major histocompatibility molecules (pMHC).

296 Class I major histocompatibility molecules were the first ligands appr

297 ymphocytes, and utilization of peptide-major histocompatibility multimers, along with imaging techniq

298 dosomal generation of peptide/class II major histocompatibility protein (MHC-II) complexes; these com

299 uggest that T cell receptor (TCR)-self-major histocompatibility protein (pMHC) interactions limit aut

300 fic differences in sensitization history and histocompatibility reduced the rate of LDKT for women by